Sabbir Ahmed, a Public Health Professional from Bangladesh having more than thirty five years of work experience in public health field the Ministry of Health & Family Welfare of Bangladesh, WHO (in country as well as with international assignment) and INGOs. His expertise primarily includes immunization, newborn and child health arena. He contributed to the development and/or update of newborn and child health policy and strategic documents. He has articles published in international journals, presented paper in national and international conferences. For last ten years, he has been working with Save the Children in Bangladesh for different MNCH projects. At present he is leading a team as the Focal Point of Pneumonia Centenary Commitment Project of Save the Children. He holds an MBBS degree and a Diploma in Public Health.

Salahuddin Ahmed is a medical doctor and public health epidemiologist with more than 20 years of experience in designing and managing epidemiological studies, disease surveillance, monitoring and evaluation of public health programs. His research focuses on improving the health and nutritional status of newborns, children, and women in low-resource settings by enhancing the understanding of the major causes of neonatal, child, and maternal morbidity, mortality and malnutrition and by designing and testing cost-effective public health interventions against them. The design and scope of his studies are diverse ranging from formative research to randomized clinical trials. He is the Director of Projahnmo Research Foundation, Bangladesh. He is an associate in the Department of International Health of Johns Hopkins Bloomberg School of Public Health, MD, USA. He is a member of the Integrated Management of Childhood Illness working group in Bangladesh. Dr. Ahmed has published more than 50 scientific articles in peer-reviewed journals and presented his studies in many different international scientific conferences. Email: sahmed@prfbd.org ORCID ID: 0000-0001-6771-0638 ResearchGate: Salahuddin Ahmed (researchgate.net)

Registrar, Paediatric Respiratory Medicine (Pulmonology), Bangladesh Shishu Hospital & Institute °FCPS (Paediatrics), DCH, MCPS (Paediatrics) °Member of -Paediatric Pulmonology Forum, Bangladesh (BPPF) -European Respiratory Society (ERS) -American Thoracic Society (ATS) °An aspiring researcher in the field of Paediatric Pulmonology °Have a special interest on the infection profile of childhood pneumonia of Bangladesh °Currently working on childhood asthma and cystic fibrosis

Werner Albrich is an internist and infectious diseases consultant at the Division of Infectious Diseases/Hospital Epidemiology, Cantonal Hospital St.Gallen, St. Gallen, Switzerland. He trained in Internal Medicine at the Ludwig-Maximilians University, Munich, Germany and the Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, USA. After a clinical fellowship in Infectious Diseases at Emory University, Atlanta, USA, he was a postdoc with Prof. Keith Klugman and Prof. Shabir Madhi at the Respiratory and Meningeal Pathogens Research Unit, Johannesburg, South Africa. His main research interests are the epidemiology, diagnostics, treatment and prevention of respiratory tract infections with a focus on pneumococcal infections. He is studying mechanisms of colonisation and invasion of the pneumococcus using an in vitro human epithelial airway model. Lately he has also been active in studying epidemiology and prognostic markers of Covid-19.

Dr. Alderson is the Bacterial Vaccine Initiative Leader with PATH’s Center for Vaccine Innovation and Access, playing a lead role in the Pneumococcal Vaccine Project, Group B Streptococcal Vaccine Project and Meningococcal Vaccine Project, Polyvalent. These projects seek to accelerate the development and licensure of affordable vaccines and ensure their availability and use in low and middle income countries. Dr. Alderson led the PATH team that worked in close collaboration with the Serum Institute of India to develop, license and WHO prequalify the 10-valent pneumococcal conjugate vaccine, PNEUMOSIL, in 2019. Dr. Alderson has more than 30 years of experience in medical research, biotechnology, pharmaceuticals and vaccine development. Prior to PATH, Dr. Alderson was Director of Immunology at GlaxoSmithKline Biologicals, Seattle, where he led preclinical work on synthetic adjuvants for a variety of vaccine targets. Prior to GSK, he was Senior Director of Immunology at Corixa Corporation where he was responsible for evaluation of adjuvants and vaccines for tuberculosis, Chlamydia and HSV. Dr. Alderson has published over 120 manuscripts in peer reviewed journals. Dr. Alderson earned his PhD in immunology at the Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia and his MBA at Seattle University.